Latest Regulatory Approvals News

The ASX has granted key waivers allowing Southern Cross Media to proceed with its acquisition of Seven West Media without shareholder approval, smoothing the way for a major media consolidation.

PainChek Limited has appointed Sasha Grant as Head of Growth for its AI-powered Infant App, aiming to scale its presence in a $15 billion global market. Early Australian adoption shows promising conversion rates as the company prepares for international expansion.

Ballard Mining advances its Mt Ida Gold Project with strategic land acquisitions, new mining lease applications, and a pending water licence increase, underpinning plans for a decade-long mine life.

Talga Group and SQM have mutually terminated their joint venture for the Aero Project in Sweden due to regulatory delays, with Talga now exploring new partnership opportunities to advance the critical minerals project.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Ark Mines has secured Environmental Authority approval for its Sandy Mitchell Rare Earths project in Queensland, marking a crucial step towards obtaining its Mining Licence. The company has also completed a major drilling program, setting the stage for an upcoming Pre-Feasibility Study.

Santana Minerals has taken a major step forward by acquiring freehold ownership of critical lands and extinguishing royalties at its Bendigo-Ophir Gold Project, enhancing project economics amid a strong gold market.

Firebrick Pharma has secured a $102,000 investment from its Philippines strategic partner, Pharma Nutria N.A., Inc., reinforcing its position ahead of the Nasodine nasal spray launch in 2026.

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.

Clarity Pharmaceuticals has inked a pivotal supply agreement with Nusano to ensure a steady source of copper-67, a critical isotope for its upcoming Phase III prostate cancer trial and future commercialisation plans.

Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.